Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

COVID-19 vaccines provide better protection against related pneumonia than previous symptomatic infection

Efrén Murillo-Zamora1,2,a, Xóchitl Trujillo3, Miguel Huerta3, Mónica Ríos-Silva4, José Guzmán-Esquível2,5,b, Verónica Benites-Godínez6,7,c, María Regina Ochoa-Castro2,d, José Alejandro Guzmán-Solórzano2, Oliver Mendoza-Cano8,e,*

1 Departamento de Epidemiología, Unidad de Medicina Familiar No. 19, Instituto Mexicano del Seguro Social, Av. Javier Mina 301, Col. Centro, C.P. 28000, Colima, Colima, México
2 Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Vilobras, C.P. 28040, Colima, Colima, México
3 Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Av. 25 de julio 965, Col. Villas San Sebastián, C.P. 28045 Colima, México
4 Universidad de Colima - CONACYT, Centro Universitario de Investigaciones Biomédicas, Av. 25 de julio 965, Col. Villas San Sebastián, C.P. 28045 Colima, México
5 Unidad de Investigación en Epidemiología Clínica, Instituto Mexicano del Seguro Social, Av. de los Maestros 149, Col. Centro, C.P. 28000, Colima, México
6 Coordinación de Educación en Salud, Instituto Mexicano del Seguro Social, Colonia Ejército de San Juan, Colima, México
7 Facultad de Ingeniería Civil, Universidad de Colima, km. 9 carretera Colima-Coquimatán, Coquimatán, C.P. 28400, Colima, México
8 Facultad de Medicina, Universidad Autónoma de Nayarit, Ciudad de la Cultura Amado Nervo, C.P. 63155, Tepic, Nayarit, México

Keywords: COVID-19 Vaccines COVID-19 SARS-CoV-2 Pneumonia

Article history:
Received 29 October 2021
Revised 22 March 2022
Accepted 20 April 2022

ABSTRACT

Objectives: To compare, in a real-world scenario, the protective effect of vaccination and previous laboratory-confirmed symptomatic infection on the risk of COVID-19 pneumonia.

Methods: A retrospective study was conducted and 46,998 adults with laboratory-confirmed COVID-19 were enrolled. Risk ratios (RRs) and 95% confidence intervals (CIs) were used to evaluate the effect of the evaluated exposures on the risk of pneumonia.

Results: In multiple analysis and after adjusting by reinfection status, vaccinated participants were at reduced risk of developing pneumonia (RR = 0.974, 95% CI 0.965–0.983). The association of having had a previous infection was not significant (RR = 1.001, 95% CI 0.996–1.004).

Conclusion: Our results suggest, and if later replicated, that COVID-19 vaccines provide better protection against pneumonia than previous symptomatic infections. Therefore, offering vaccination to all eligible subjects despite past COVID-19 infections might be relevant to reducing the pandemic-related burden.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Background

The burden of the COVID-19 pandemic in Mexico has been high and by mid-October 2021, more than 3.7 million laboratory-confirmed cases have been registered, with more than 280 thousand deaths.

The COVID-19 vaccines represent a major step toward ending the pandemic. Published in vitro data suggest a better neutralization of some circulating SARS-CoV-2 variants after COVID-19 vaccination when compared with natural infection (Deng et al., 2021; Stamatakis et al., 2021). However, and to the best of our knowledge, studies analyzing the benefit of vaccination for previously infected subjects in a real-world scenario are scarce (Shrestha et al., 2022).
The aim of this study was to compare the protective effect of vaccination and previous laboratory-confirmed symptomatic infection on the risk of COVID-19 pneumonia. In addition, we evaluated the interaction between both exposures on the risk of severe illness.

Methods

We conducted a retrospective and nationwide cohort study in Mexico. Eligible subjects were adults with laboratory-confirmed COVID-19 (RT-PCR or rapid antigen testing) and symptoms onset from February to July 2021. Participants were identified from nominal records found in a national normative system for the epidemiological surveillance of respiratory viruses.

The vaccinated subjects were those with two doses of any COVID-19 vaccine or a single dose (any COVID-19 vaccine) at 15 or more days before illness onset. The second-time laboratory-confirmed SARS-CoV-2 infection was defined by the reappearance of symptoms of COVID-19 at more than 90 days after the initial laboratory-confirmed illness.

Pneumonia was the main outcome and it was defined by clinical (fever or chills, cough, shortness of breath, and tachypnea) and radiographic findings (ground-glass patterns in X-ray or computed tomography imaging) that required hospital admission. Risk ratios (RRs) and 95% confidence intervals (CIs) were estimated using generalized linear regression models and were used to evaluate the association between the analyzed exposures and the risk of COVID-19 pneumonia. The interaction between vaccination and reinfection was also tested.

Results

Data from 46,998 participants were analyzed for a total follow-up of 379,475 person-days. The study profile is shown in Supplementary Data 1. The overall frequency of vaccination and second-time infection in the study sample was 3.3% and 0.2%, respectively. Later, the mean (± standard deviation) elapsed days between episodes was 183.9 (± 69.8 days).

The overall rate of pneumonia was 4.4 cases per 1000 person-days, respectively. According to vaccination status, the pneumonia rate was 4.4 and 3.6 cases per 1000 person-days in unvaccinated and vaccinated participants, respectively.

Compared with participants with no severe manifestations, patients with pneumonia were older (mean age ± standard deviation: 61.9 ± 15.0 vs 41.2 ± 15.6, P-value < 0.001) and were more likely to be male (56.5% vs 48.9%) and have any comorbidity. Table 1 summarizes the characteristics of study subjects for selected variables.

| Table 1 | Characteristics of the study sample for selected variables, Mexico 2021 |
|-----------------------------------------------|------------------------|------------------------|
| **Characteristic**                          | **COVID-19 pneumonia** |
|                                              | **No (n = 45,337)**    | **Yes (n = 1,661)**    | **p**      |
| **Gender**                                   |                        |                        |            |
| Female                                       | 23,170                  | 723                    | (43.5)     | < 0.001 |
| Male                                         | 22,167                  | 938                    | (56.5)     | < 0.001 |
| **Age (years), mean ± SD**                   |                        |                        |            |
| Age group (years)                            |                        |                        |            |
| 18–27                                       | 9,404                   | 27                     | (1.6)      | < 0.001 |
| 28–33                                       | 8,833                   | 47                     | (2.8)      | < 0.001 |
| 35–42                                       | 8,890                   | 111                    | (6.7)      | < 0.001 |
| 43–54                                       | 9,112                   | 299                    | (18.0)     | < 0.001 |
| 55 or above                                 | 9,098                   | 1,177                  | (70.9)     | < 0.001 |
| **Previous SARS-CoV-2 symptomatic infection**|                        |                        |            |
| No                                           | 45,222                  | 1,658                  | (99.8)     | 0.559   |
| Yes                                          | 115                     | 3                      | (0.2)      | 0.075   |
| **COVID-19 vaccinated**                      |                        |                        |            |
| No                                           | 43,830                  | 1,619                  | (97.5)     | < 0.001 |
| Yes                                          | 1,507                   | 42                     | (2.5)      | < 0.001 |
| **Administered vaccine**                     |                        |                        |            |
| AZD1222 Covishield                          | 593                     | 10                     | (23.8)     | < 0.001 |
| BNT162b2                                     | 532                     | 15                     | (35.7)     | < 0.001 |
| Ad5-nCoV Covidecia                           | 173                     | 4                      | (9.5)      | < 0.001 |
| CoronaVac                                    | 72                      | 0                      | (0)        | < 0.001 |
| Other                                        | 11                      | 1                      | (2.4)      | < 0.001 |
| Unknown                                      | 126                     | 12                     | (28.6)     | < 0.001 |
| **Personal history of:**                    |                        |                        |            |
| Tobacco use (current)                        |                        |                        |            |
| No                                           | 42,171                  | 1,430                  | (86.1)     | < 0.001 |
| Yes                                          | 3,166                   | 231                    | (13.9)     | < 0.001 |
| **Asthma**                                   |                        |                        |            |
| No                                           | 44,266                  | 1,620                  | (97.5)     | 0.780   |
| Yes                                          | 1,071                   | 41                     | (2.5)      | < 0.001 |
| **Type 2 diabetes mellitus**                 |                        |                        |            |
| No                                           | 40,262                  | 974                    | (58.6)     | < 0.001 |
| Yes                                          | 5,075                   | 687                    | (41.4)     | < 0.001 |
| **Immunosuppression**                        |                        |                        |            |
| No                                           | 44,992                  | 1,610                  | (96.9)     | < 0.001 |
| Yes                                          | 345                     | 51                     | (3.1)      | < 0.001 |

Abbreviations: COVID-19, Coronavirus disease 2019; SD, Standard deviation; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2.

Notes: 1) The absolute (n) and relative (%) frequencies are presented except if the arithmetic mean ± standard deviation is specified; 2) The p-value of ji-squared or t-tests are presented as corresponding.

- The vaccinated subjects were those with 2 shots of any COVID-19 vaccine or a single shot (any COVID-19 vaccine) at 15 or more days before illness onset.
- Restricted to 1,549 participants that were classified as COVID-19 vaccinated.
- Immunosuppression referred to any cause of the related deficiency except for type 2 diabetes mellitus or renal impairment.
In multiple analysis (Table 2) and after adjustment by a history of symptomatic COVID-19 and other comorbidities, vaccinated subjects were at decreased risk of developing pneumonia (RR = 0.974, 95% CI 0.965–0.983). The association of having a previous COVID-19 episode was not significant (RR = 1.001, 95% CI 0.969–1.034). The interaction between vaccination and reinfection status was not significant (P-value = 0.846).

Discussion

The results from our observational study suggest that COVID-19 vaccines provide better protection against pneumonia than previous symptomatic infections. Our results also highlight the relevance of offering vaccination to all eligible subjects despite a previous symptomatic SARS-CoV-2 infection.

By January 2022 and according to official data of the government of Mexico, 82 million Mexicans (64% of the total population of the country) had been fully vaccinated against COVID-19. The AZD1222 Covishield (AstraZeneca) or BNT162b2 (Pfizer, Inc./BioNTech) vaccines had been administered to around 7 of 10 immunized subjects.

In our study and as presented in Supplementary Data 2, adults integrating the vaccinated group were older than those from the reinfection group (49.9 ± 14.6 vs 40.1 ± 11.7 years, P-value < 0.001). In consequence to the highest mean age, type 2 diabetes mellitus was frequent (18.3% vs 11.0%, P-value= 0.045). The COVID-19 strategy vaccination, where older subjects were prioritized, might be determining the observed differences.

Previously published data suggest that unvaccinated patients with COVID-19 who recovered from severe illness are at increased risk of developing pneumonia after reinfection (Murillo-Zamora et al., 2021). This may be secondary to the persistence of factors conditioning severe manifestations and support the benefit of vaccinating to all eligible adults.

After a natural infection, the length of immunity under endemic conditions is above 90 days (Townsend et al., 2021). However, and against the emergence of variants of concern, the protective effect of circulating antibodies from recovered patients who had COVID-19 might be weak (Planas et al., 2021).

The limitations of our study must be cited. First, no serologic data were collected and therefore, only symptomatic infections were evaluated. Second, we lacked genomic data to ensure that second-time infections were reinfections. However, in our study sample, the mean elapsed days between illness episodes were about six months (175 ± 64 days), which might discard itself a large proportion of persistent SARS-CoV-2 infections (Vibholm et al., 2021). In vaccinated adults, the mean days between the last shot and illness onset were 69 ± 47 days. Third, and as cited previously, the interval between episodes in reinfection cases was longer (P-value < 0.001) than the period from the last vaccine shot to illness onset in vaccinated individuals. As antibodies titer may wane with time (Gaebler et al., 2021), these differences might have an impact on the presented results. Finally, we were unable to identify specific pathogenic variants or disease severity of the first episode to obtain stratified estimates of interest.

Conclusions

The COVID-19 vaccines provide better protection against pneumonia than previous symptomatic infection. Therefore, offering immunization to all eligible subjects despite the presence of a previous symptomatic episode of SARS-CoV-2 infection might be useful to reduce the social and economic burden of the COVID-19 pandemic.

Declaration of competing interests

The authors have no competing interests to declare.
EMZ conceived and designed the experiments and also wrote the first draft of the manuscript; XT and JGE did data analysis and data collection; MH and VBG contributed to the methodology and writing—review and editing; MRS, MROC, and JAGS contributed with revisions and data analysis; and OMC performed the experiments, analyzed the data, and is responsible for the final version of the manuscript that has been read and approved by all authors.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Funding

This research received no external funding.

Ethics approval and consent to participate

This study was approved by the Local Health Research Committee of the Mexican Institute of Social Security (approval R-601-2020-015).

References

Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-Gonzalez A, Glasner DR, Reyes KR, Giwa AS, Reddy NP, Sanchez C, San Martin S, Federman JCheng, Balcerak J, Taylor J, Streithorst JA, Miller S, Sreekumar R, Chen PY, Schulze-Gahmen U, Taha TY, Hayashi JM, Simonneau CR, Kumar GR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Frankino PA, Shivram H, Lareau LF, Wyman SK, Ott M, Andino R, Chiu CY. Transmigration, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 2021;184:3426–37 e8.

Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes CO, Brani Y, Breton C, Hagglov T, Mendoza P, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tanklevich M, Martinez-Delgado G, Yee J, Patel R, Dizon J, Unson-O’Brien C, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Schwartz RE, Hatziioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig MC. Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591:639–44.

Murillo-Zamora E, Mendoza-Cano O, Delgado-Enciso I, Hernandez-Suarez CM. Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection. Public Health 2021;193:113–15.

Planas D, Bruel T, Grzelak I, Guivel-Benhassine F, Staropoli I, Porro F, Planchais C, Buchrieser J, Rajah MM, Bishop E, Albert M, Donati F, Prot M, Behillil S, Enouf V, Maquart M, Smati-Lafarge M, Varon E, Schortgen F, Yahyaoui L, Gonzalez M, De Seze J, Pere H, Veyer D, Seve A, Simon-Loriere E, Fali-Krimer S, Stefic K, Mouquet H, Hocqueloux L, van der Werf S, Prazuck T, Schwartz O. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med 2021;27:917–24.

Shrestha NK, Burke PC, Nowacki AS, Terpeluk P, Gordon SM. Necessity of COVID-19 vaccination in persons who have already had COVID-19. Clin Infect Dis 2022;cia022.

Stamatatos I, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccine boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 2021:eabg9175.

Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, Ruddle NH, Galvani AP, Dornburg A. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe 2021;2:e666–75.

Vibhorg LK, Nielsen SSF, Pahuš MH, Frattari CS, Olesen R, Andersen R, Monrad I, Andersen AHF, Thomsen MM, Konrad CV, Andersen SD, Hejøn JF, Gunst JD, Østergaard L, Sgaard OS, Schleimann MH, Tolstrup M. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. Ebiomedicine 2021;64.